MARK2 is a serine/threonine kinase that phosphorylates microtubule-associated proteins (MAPs) including tau, regulating microtubule dynamics and neuronal polarity. Dysregulation of MARK2 activity contributes to tau hyperphosphorylation in Alzheimer's disease and other tauopathies.
[^2]
| Property | Value |
|----------|-------|
| Gene Symbol | MARK2 |
| Full Name | MAP/Microtubule Affinity-Regulating Kinase 2 |
| Aliases | EMK1, Par-1b, ELKL motif kinase 1 |
| Chromosomal Location | 11q12.2 |
| NCBI Gene ID | 2011 |
| OMIM ID | 600526 |
| Ensembl ID | ENSG00000072518 |
| UniProt ID | Q7KZI7 |
| Encoded Protein | MARK2 Protein |
| Associated Diseases | Alzheimer's disease, tauopathies, autism spectrum disorder |
MARK2 (MAP/Microtubule Affinity-Regulating Kinase 2), also known as Par-1b or EMK1, is a member of the AMPK-related kinase family. It was originally identified as a partitioning-defective (Par) gene product in C. elegans, where it is essential for asymmetric cell division and polarity establishment. In mammals, MARK2 plays critical roles in neuronal polarity, axon specification, microtubule dynamics, and intracellular transport. It is one of the primary kinases responsible for phosphorylating tau at the KXGS motifs (Ser262 and Ser356) within the microtubule-binding repeats, a modification that profoundly reduces tau's affinity for microtubules and is observed early in Alzheimer's disease pathogenesis.
¶ Tau Phosphorylation and Microtubule Regulation
MARK2 is one of four MARK family kinases (MARK1, MARK2, MARK3, MARK4) that phosphorylate tau at KXGS motifs within microtubule-binding repeats:
- Ser262 phosphorylation — The primary MARK2 target on tau; phosphorylation at this site alone reduces tau-microtubule binding by ~10-fold
- Ser356 phosphorylation — Second major target; combined Ser262/Ser356 phosphorylation virtually abolishes tau-microtubule interaction
- Microtubule destabilization — By detaching tau, MARK2 increases microtubule dynamic instability, enabling cytoskeletal remodeling
- Transport regulation — MARK2-mediated tau phosphorylation clears microtubule tracks, facilitating kinesin and dynein-dependent axonal transport
MARK2 is a central regulator of neuronal polarization:
- Axon specification — MARK2 activity is required for the break in symmetry that selects one neurite to become the axon
- Par complex interaction — MARK2 phosphorylates Par-3 (PARD3), disrupting the Par-3/Par-6/aPKC polarity complex and establishing axonal identity
- Growth cone dynamics — Regulates actin-microtubule cross-talk at the growth cone through MAP phosphorylation
- Dendritic spine morphogenesis — MARK2 localizes to postsynaptic densities and regulates spine shape through PSD-95 phosphorylation
¶ Cell Polarity and Epithelial Function
Beyond neurons, MARK2 functions broadly in cell polarity:
- Epithelial polarity — Phosphorylates Par-3 at tight junctions, regulating apical-basolateral polarity
- Wnt signaling — Participates in non-canonical Wnt/PCP (planar cell polarity) signaling
- Energy sensing — Activated by LKB1 (upstream kinase), linking cellular energy status to cytoskeletal regulation
- Insulin signaling — MARK2 knockout mice show improved insulin sensitivity, suggesting metabolic regulatory roles
MARK2 is tightly regulated by multiple mechanisms:
- LKB1 activation — The master kinase LKB1/STK11 phosphorylates MARK2 at Thr208 in the activation loop, the primary activating event
- aPKC inhibition — Atypical protein kinase C phosphorylates MARK2 at Thr595, targeting it for degradation and establishing polarity asymmetry
- GSK3β priming — GSK3β can prime MARK2 substrates, creating cooperative phosphorylation cascades on tau
- MARKK/TAO1 activation — Thousand-and-one kinase (TAO1) also activates MARK2 by activation loop phosphorylation
- 14-3-3 binding — Phosphorylated MARK2 binds 14-3-3 proteins, which sequester it in the cytoplasm
MARK2 is strongly implicated in AD pathogenesis through multiple mechanisms:
- Early tau pathology — Phosphorylation of tau at Ser262 (a MARK site) is one of the earliest pathological tau modifications, preceding PHF formation and NFT accumulation
- Amyloid-beta activation — Aβ oligomers activate MARK2 through disruption of the LKB1-MARK signaling axis, creating a feed-forward loop between amyloid and tau pathology
- Synaptic toxicity — MARK2-dependent tau phosphorylation in dendritic spines contributes to postsynaptic dysfunction and spine loss in AD
- Axonal transport deficits — Excessive MARK2 activity strips tau from microtubules, disrupting axonal transport of mitochondria, vesicles, and signaling endosomes
- Kinase cascade interaction — MARK2 cooperates with CDK5 and GSK3β in sequential tau phosphorylation, each kinase priming sites for the others
- MAPT mutations — Several FTD-causing MAPT mutations (e.g., P301L, V337M) alter tau's susceptibility to MARK2 phosphorylation
- Increased MARK activity — FTLD-Tau brain tissue shows elevated MARK family kinase activity
- De novo mutations — Rare de novo MARK2 variants have been identified in individuals with autism spectrum disorder
- Neuronal migration — MARK2 regulates neuronal migration during cortical development; disruption may contribute to neurodevelopmental phenotypes
- Parkinson's disease — MARK2 phosphorylation of tau may contribute to tau co-pathology observed in PD
- Traumatic brain injury — MARK activity is elevated following TBI, potentially linking acute injury to chronic tauopathy
MARK2 shows broad but enriched neural expression:
- Brain regions — Highly expressed in hippocampus (CA1, CA3, dentate gyrus), cerebral cortex (layers II-VI), cerebellum (Purkinje cells), and basal ganglia
- Cell types — Predominantly neuronal; also expressed in astrocytes and oligodendrocytes
- Subcellular localization — Cytoplasm, axon initial segment, growth cones, postsynaptic densities, cell cortex
- Developmental profile — Expressed from early embryonic development; critical during neuronal polarization (E13-E18 in mouse)
- Allen Brain Atlas — MARK2 expression data